FDA approves Spark's gene therapy for rare form of blindness

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Spark Therapeutics Inc's treatment for a rare form of blindness, marking the first time the agency has approved a gene therapy for an inherited disease.